Table 1.
Socio-demographic and medical history data of the study population by age-dependent categories
| Patients N = 1379 N (%) |
18–44 years, N = 250 n (%) |
45–54 years, N = 246 n (%) |
55–64 years, N = 247 n (%) |
65–74 years, N = 237 n (%) |
75–84 years, N = 235 n (%) |
≥85 years, N = 164 n (%) |
P value | |
|---|---|---|---|---|---|---|---|---|
| Socio-demographic data | ||||||||
| Male gender | 739 (53.6) | 136 (54.4) | 133 (54.1) | 124 (50.2) | 140 (59.1) | 125 (53.2) | 80 (48.8) | 0.545 |
| Living in nursing home | 33 (2.4) | 1 (0.4) | 2 (0.8) | 1 (0.4) | 4 (1.7) | 6 (2.6) | 19 (11.7) | < 0.001 |
| Medical history | ||||||||
| Current smoking | 61 (4.4) | 9 (3.6) | 9 (3.7) | 13 (5.3) | 21 (8.9) | 6 (2.6) | 3 (1.8) | < 0.001 |
| Hypertension | 559 (40.5) | 6 (2.4) | 41 (16.7) | 78 (31.6) | 148 (62.4) | 167 (71.1) | 119 (72.6) | < 0.001 |
| Diabetes mellitus | 265 (19.2) | 7 (2.8) | 17 (6.9) | 35 (14.2) | 73 (30.8) | 80 (34.0) | 53 (32.3) | < 0.001 |
| Dyslipidemia | 523 (37.9) | 8 (3.2) | 38 (15.4) | 96 (38.9) | 146 (61.6) | 147 (62.6) | 88 (53.7) | < 0.001 |
| Obesity | 131 (9.5) | 20 (8.0) | 25 (10.2) | 26 (10.5) | 28 (11.8) | 24 (10.2) | 8 (4.9) | 0.664 |
| Chronic respiratory disease | 239 (17.3) | 17 (6.8) | 24 (9.8) | 30 (12.1) | 59 (24.9) | 62 (26.4) | 47 (28.7) | < 0.001 |
| Heart disease | 237 (17.2) | 6 (2.4) | 7 (2.8) | 19 (7.7) | 49 (20.7) | 70 (29.8) | 86 (52.4) | < 0.001 |
| Peripheral artery disease | 36 (2.6) | 0 (0.0) | 0 (0.0) | 3 (1.2) | 7 (3.0) | 13 (5.5) | 13 (7.9) | < 0.001 |
| Cerebrovascular disease | 58 (4.2) | 0 (0.0) | 1 (0.4) | 3 (1.2) | 15 (6.3) | 24 (10.2) | 15 (9.1) | < 0.001 |
| Dementia | 67 (4.9) | 0 (0.0) | 1 (0.4) | 1 (0.4) | 8 (3.4) | 18 (7.7) | 39 (23.8) | < 0.001 |
| Chronic renal disease | 109 (7.9) | 1 (0.4) | 7 (2.8) | 11 (4.5) | 29 (12.2) | 39 (16.6) | 22 (13.4) | < 0.001 |
| Liver disease | 43 (3.1) | 0 (0.0) | 8 (3.3) | 11 (4.5) | 10 (4.2) | 7 (3.0) | 7 (4.3) | 0.031 |
| Cancer | 130 (9.4) | 4 (1.6) | 13 (5.3) | 19 (7.7) | 30 (12.7) | 41 (17.4) | 23 (14.0) | < 0.001 |
| HIV | 16 (1.2) | 4 (1.6) | 5 (2.0) | 4 (1.6) | 3 (1.3) | 0 (0.0) | 0 (0.0) | 0.020 |
| Connective tissue disease | 20 (1.4) | 0 (0.0) | 5 (2.0) | 3 (1.2) | 3 (0.8) | 4 (1.7) | 6 (3.7) | 0.012 |
| Baseline functional status | ||||||||
| Independent BADL | 1220 (91.4) | 246 (98.8) | 235 (98.3) | 237 (97.9) | 217 (94.3) | 198 (87.2) | 87 (58.8) | < 0.001 |
| Partially dependent BADL | 64 (4.8) | 0 (0.0) | 2 (0.8) | 5 (2.1) | 8 (3.5) | 17 (7.5) | 32 (21.6) | |
| Total dependent BADL | 51 (3.8) | 3 (1.2) | 2 (0.8) | 0 (0.0) | 5 (2.2) | 12 (5.3) | 29 (19.6) | |
| Chronic treatment at home | ||||||||
| ACEis / ARBs | 440 (31.9) | 6 (2.4) | 30 (12.2) | 63 (25.5) | 111 (46.8) | 138 (58.7) | 92 (56.1) | < 0.001 |
| Anticoagulation | 124 (9.0) | 1 (0.4) | 2 (0.8) | 9 (3.6) | 20 (8.4) | 43 (18.3) | 49 (29.9) | < 0.001 |
| Antiplatelet agent | 208 (15.1) | 1 (0.4) | 10 (4.1) | 20 (8.1) | 52 (21.9) | 66 (28.1) | 59 (36.0) | < 0.001 |
| Immunosuppressive treatment | 95 (6.9) | 3 (1.2) | 13 (5.3) | 16 (6.5) | 22 (9.3) | 24 (10.2) | 17 (10.4) | < 0.001 |
P value for lineal trend. Numbers in bold mean value P < 0.05
HIV human immunodeficiency virus, BADL basic activities of daily living, ACE angiotensin-converting enzyme inhibitors, ARBs angiotensin II receptor blockers